Clinical Trials
- Colorectal Cancer, Stomach and Esophagus, Kidney Cancer, Head and Neck Cancers, Lung Cancer, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Cancer, Breast Cancer
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
- Ages18 years and older
- GenderBoth
- Lung Cancer
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
- Lung Cancer, Pediatric Cancers
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment (HEART)
- Ages18 years and older
- GenderBoth
- Lung Cancer, Phase 1 Cancers, Breast Cancer, Gynecological Cancers
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors
- Lung Cancer
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
- Lung Cancer
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
- Lung Cancer
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
- Colorectal Cancer, Sarcoma Cancers, Brain and Other Nervous System Cancers, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Other Cancers, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Leukemia, Melanoma, Thyroid and Other Endocrine Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer
NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
- Ages18 years and older
- GenderBoth
- Colorectal Cancer, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Phase 1 Cancers, Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Lung Cancer
Phase 2 Trial of Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous Non-Small Cell Lung Cancer